Phase 3 trial comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Science and Health expanded on Eddy's view that sickness was a mental error. People said that simply reading Science and Health had healed them; cures were claimed for everything from cancer to blindness. Eddy wrote in the New York Sun in December 1898, in an article called "To the Christian World," that she had personally healed tuberculosis, diphtheria and "at one visit a cancer that had eaten the flesh of the neck and exposed the jugular vein so that it stood out like a cord. I have physically restored sight to the blind, hearing to the deaf, speech to the dumb, and have made the lame walk." Eddy wrote that her views had derived, in part, from having witnessed the apparent recovery of patients she had treated with homeopathic remedies so diluted they were drinking plain water. She concluded that Divine Mind was the healer:
==== Australia ==== On 10 March 2022, Brazil's Agriculture Ministry announced the country was holding talks with Australia about agricultural trade agreements regarding wheat, barley and pork trade as well as sustainable agriculture including research projects between both countries.
=== Suspended === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – alcoholism Rocavorexant (C4X-3256; INDV-2000) – orexin OX1 receptor antagonist – opioid-related disorders Tetrodotoxin (9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin) – voltage-gated sodium channel blocker
=== Post-Tang dynasty === The great migration of Chinese people south during the invasions preceding and during the Song dynasty increased the relative importance of southern Chinese staples such as rice and congee. Su Dongpo has improved the red braised pork as Dongpo pork. The dietary and culinary habits also changed greatly during this period, with many ingredients such as soy sauce and Central Asian influenced foods becoming widespread and the creation of important cookbooks such as the Shanjia Qinggong (Chinese: 山家清供; pinyin: Shānjiā qīnggòng) and the Wushi Zhongkuilu (Chinese: 吳氏中饋錄; pinyin: Wúshì zhōngkuìlù) showing the respective esoteric foods and common household cuisine of the time. The Yuan and Qing dynasties introduced Mongolian and Manchu cuisine, warm northern dishes that popularized hot pot cooking. During the Yuan dynasty many Muslim communities emerged in China, who practiced a porkless cuisine now preserved by Hui restaurants throughout the country. Yunnan cuisine is unique in China for its cheeses like Rubing and Rushan cheese made by the Bai people, and its yogurt, the yogurt may have been due to a combination of Mongolian influence during the Yuan dynasty, the Central Asian settlement in Yunnan, and the proximity and influence of India and Tibet on Yunnan. As part of the last leg of the Columbian Exchange, Spanish and Portuguese traders began introducing foods from the New World to China through the port cities of Canton and Macau.
Sources: en.wikipedia.org
Gottron's papules are violaceous erythematous papules that commonly occur overlying the dorsal interphalangeal (DIP) or metacarpophalangeal joints (MCP), as well as the elbows or knee joints. They are found in approximately 70 percent of patients diagnosed with dermatomyositis.
=== Benefits of plasma over serum === Plasma preparation is quick, as it is not coagulated. Serum sample preparation requires about 30 minutes of waiting time before it can be centrifuged and then analyzed. However, coagulation can be hastened down to a few minutes by adding thrombin or similar agents to the serum sample. Compared to serum, 15–20% larger volume of plasma can be obtained from a blood sample of certain size. Serum lacks some proteins that partake in coagulation and increase the sample volume. Serum preparation can cause measurement errors by increasing or decreasing the concentration of the analyte that is meant to be measured. For example, during coagulation, blood cells consume blood glucose and platelets increase the sample content of compounds like potassium, phosphates and aspartate transaminase by secreting them. Glucose or these other compounds may be the analytes.
Some paleolithic hunter-gatherers consumed a significant amount of meat and possibly obtained most of their food from hunting, while others were believed to have a primarily plant-based diet. Most, if not all, are believed to have been opportunistic omnivores. One hypothesis is that carbohydrate tubers (plant underground storage organs) may have been eaten in high amounts by pre-agricultural humans. It is thought that the Paleolithic diet included as much as 1.65–1.9 kg (3.6–4.2 lb) per day of fruit and vegetables. The relative proportions of plant and animal foods in the diets of Paleolithic people often varied between regions, with more meat being necessary in colder regions (which were not populated by anatomically modern humans until c. 30,000 – c. 50,000 BP). It is generally agreed that many modern hunting and fishing tools, such as fish hooks, nets, bows, and poisons, were not introduced until the Upper Paleolithic and possibly even Neolithic. The only hunting tools widely available to humans during any significant part of the Paleolithic were hand-held spears and harpoons. There is evidence of Paleolithic people killing and eating seals and elands as far as c. 100,000 BP. On the other hand, buffalo bones found in African caves from the same period are typically of very young or very old individuals, and there is no evidence that pigs, elephants, or rhinos were hunted by humans at the time. Paleolithic peoples suffered less famine and malnutrition than the Neolithic farming tribes that followed them.
=== iDP === Internal DisplayPort (iDP) is a standard that defines an internal link between a digital TV system on a chip controller and the display panel's timing controller. Version 1.0 was approved in April 2010. It aims to replace currently used internal FPD-Link lanes with a DisplayPort connection. iDP features a unique physical interface and protocols, which are not directly compatible with DisplayPort and are not applicable to external connection, however they enable very high resolution and refresh rates while providing simplicity and extensibility. iDP features a non-variable 2.7 GHz clock and is nominally rated at 3.24 Gbit/s per lane, with up to sixteen lanes in a bank, resulting in a six-fold decrease in wiring requirements over FPD-Link for a 1080p24 signal; other data rates are also possible. iDP was built with simplicity in mind so doesn't have an AUX channel, content protection, or multiple streams; it does however have frame sequential and line interleaved stereo 3D.
The baculovirus-insect cell expression system has the ability to express a variety of recombinant proteins at high levels and provide significant eukaryotic protein processing capabilities, including phosphorylation, glycosylation, myristoylation and palmitoylation. Similar to mammalian cells, proteins expressed are mostly soluble, accurately folded, and biologically active. However, it has slower growth rate and requires higher cost of growth medium than bacteria and yeast, and confers toxicological risks. A notable feature is the existence of elements of control that allow for the expression of secreted and membrane-bound proteins in Baculovirus-insect cells. Licensed recombinant subunit vaccines that utilises baculovirus-insect cells include Cervarix (papillomavirus C-terminal truncated major capsid protein L1 types 16 and 18) and Flublok Quadrivalent (hemagglutinin (HA) proteins from four strains of influenza viruses).
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.